Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial

Brose Marcia S.; Schlumbeger Martin; Jeffers Michael; Kappeler Christian; Meinhardt Gerold; Pena Carol E. A.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial

【24h】

Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial

机译：分化甲状腺癌患者临床结果的生物标志物及其关联分析：Sorafenib阶段决定试验的细胞分析

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: The phase III DECISION trial (NCT00984282; EudraCT:2009-012007-25) established sorafenib efficacy in locally recurrent or metastatic, progressive, differentiated thyroid cancer (DTC) refractory to radioactive iodine. We conducted a retrospective, exploratory biomarker analysis of patients from DECISION.

机译：目的：第三阶段决定试验（NCT00984282; eudract：2009-012007-25）在局部复发或转移性，渐进性的，分化的甲状腺癌（DTC）难治于放射性碘的索拉非尼疗效建立了索拉非尼疗效。我们对决策的患者进行了回顾性，探索性生物标志物分析。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2019年第24期|共11页
作者
Brose Marcia S.; Schlumbeger Martin; Jeffers Michael; Kappeler Christian; Meinhardt Gerold; Pena Carol E. A.;
展开▼
作者单位

Univ Penn Abramson Canc Ctr Dept Otorhinolaryngol Head &

Neck Surg Philadelphia PA 19104 USA;

Gustave Roussy Villejuif France;

Bayer HealthCare Pharmaceut Whippany NJ USA;

Bayer HealthCare Pharmaceut Whippany NJ USA;

Bayer HealthCare Pharmaceut Whippany NJ USA;

Bayer HealthCare Pharmaceut Whippany NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial [J] . Brose Marcia S., Schlumbeger Martin, Jeffers Michael, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第24期

机译：分化甲状腺癌患者临床结果的生物标志物及其关联分析：Sorafenib阶段决定试验的细胞分析
2. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer [J] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, BMC Cancer . 2011,第1期

机译：决策的原理和设计：一项双盲，随机，安慰剂对照的III期临床试验，评估索拉非尼在局部晚期或转移性放射性碘（RAI）难治性分化型甲状腺癌患者中的疗效和安全性
3. Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial [J] . Carol Pena, Chetan Lathia, Minghua Shan, Clinical cancer research: an official journal of the American Association for Cancer Research . 2010,第19期

机译：预测晚期肾细胞癌患者预后的生物标志物：肾癌全球评估试验中索拉非尼III期治疗方法的结果
4. Clinical Engineering and Clinical Dosimetry in Patients with Differentiated Thyroid Cancer Undergoing Thyroid Remnant Ablation with Radioiodine-131 [C] . M. Medvedec, D. Dodig 12th Mediterranean conference on medical and biological engineering and computing 2010 . 2010

机译：放射性碘131消融甲状腺分化型甲状腺癌患者的临床工程和临床剂量
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. Rationale and design of decision: a double-blind randomized placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer [O] . Marcia S Brose, Christopher M Nutting, Steven I Sherman, 2011

机译：决策的依据和设计：一项双盲随机安慰剂对照的III期临床试验评估索拉非尼在局部晚期或转移性放射性碘（RAI）-难治性分化型甲状腺癌患者中的疗效和安全性
7. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial [O] . Marcia S. Brose, Martin Schlumbeger, Michael Jeffers, 2019

机译：分化甲状腺癌患者临床结果的生物标志物及其关联分析：Sorafenib阶段决定试验的细胞分析

Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial

摘要

著录项

相似文献

相关主题

期刊订阅